Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Geriatric Hip Fracture Surgery
NCT03923959Phase 3Completed
- Sponsor
- Lancaster General Hospital
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in Hip fracture (2 arms), sponsored by Lancaster General Hospital. Primary endpoint: Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells at 3 months. Started Feb 2020; status: completed.
02
Drugs
tranexamic acid
03
Conditions
Hip fracture
Beyond the preview
Go deeper on NCT03923959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923959.